– USA, NC – Evecxia Therapeutics, Inc., the leader in serotonin synthesis amplification to treat neuropsychiatric disorders, today announced the appointments of Allan Shaw and Dr. Elliot Ehrich (MD) to its Board of Directors, bringing with them decades of leadership experience in the biopharmaceutical industry.
“We welcome Allan and Elliot to our team. We are excited to draw on their impressive backgrounds as we continue to progress Evecxia’s drug candidates through clinical development and towards commercialization,. Allan’s financial and deal-making expertise and Elliot’s track record of developing CNS drugs, from research through approval, will position Evecxia well going forward, as we advance our drug candidates EVX-101 and EVX-301 into Phase 2 clinical trials and continue to further build out the Company” said CEO, Dr. Jacob Jacobsen.
About Allan L Shaw
Allan Shaw brings to Evecxia more than 20 years of leadership experience managing public companies from financial, operational, and strategic global business perspectives. He currently serves as CFO of Portage Biotech and has served on seven public boards including chairing three audit committees and three compensation committees. Mr. Shaw is also a five-time public company CFO and an experienced deal executive, who has structured, directed, negotiated, and closed over $4 billion in public and private financings, for several companies, including several IPOs.
Allan Shaw received a B.S. from the State University of New York at Oswego and is a Certified Public Accountant in the state of New York as well as a Chartered Global Management Accountant.
About Dr. Elliot Ehrich
Dr. Elliot Ehrich is currently EVP and CMO at LifeMine Therapeutics. Prior to LifeMine, Dr. Ehrich was President of Skyhawk Therapeutics and a Venture Partner at 5AM Ventures. From 2000 to 2018, Dr. Ehrich was at Alkermes. Over this span of 18 years, he rose through the ranks to lead all research and development activities at Alkermes. As EVP of Research & Development and CMO, Dr. Ehrich initiated a transformation of Alkermes’ R&D focus from medicines based on drug delivery technology to a diverse portfolio of novel, proprietary small molecule therapeutics. In doing so, he led the discovery, development, and, ultimately, the FDA registration of a series of medicines for multiple therapeutic indications, including schizophrenia, alcohol and opioid dependence, and multiple sclerosis. Prior, Dr. Ehrich spent 7 years at Merck Research Labs working in clinical pharmacology and clinical development.
Dr. Ehrich received a B.A. at Princeton University and an M.D. from Columbia University.
About Evecxia Therapeutics
Evecxia’s mission is to help patients suffering from disabling neuropsychiatric conditions for which current therapies are inadequate. Evecxia is the first company dedicated to realizing the therapeutic potential of amplifying serotonin synthesis to treat brain disorders. Serotonin synthesis amplification builds a stronger, more dynamic, more resilient brain endogenous serotonin system. Serotonin synthesis amplification is a distinct pharmacology from targeting serotonin transporters (e.g., serotonin reuptake inhibitors) and receptors (e.g., psilocybin). Evecxia deploys 5-hydroxytryptophan (5-HTP), the natural serotonin precursor, delivered via proprietary drug delivery technologies, to achieve sustained brain serotonin synthesis amplification. Evecxia has two Phase 2 clinical-stage drug candidates in development. EVX-101 is being developed as an adjunctive treatment for depression when first-line serotonin reuptake inhibitor antidepressants alone are inadequate. EVX-301 is being developed as a rescue therapy for patients hospitalized for acute suicidal crises.
For more information: https://evecxia.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.